Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents

Current Opinion in Neurology

Volumn 23, Issue 6, 2010, Pages 592-596

  Perry, James R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

angiogenesis; anticoagulant therapy; glioma; thrombosis

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; CILENGITIDE; DALTEPARIN; DEXAMETHASONE; DOXORUBICIN; HEPARIN; IRINOTECAN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; PAZOPANIB; SORAFENIB; SUNITINIB; TAMOXIFEN; THALIDOMIDE; TINZAPARIN; VANDETANIB; VATALANIB; XL 184;

ADJUVANT THERAPY; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR RISK; DEEP VEIN THROMBOSIS; GLIOMA; HUMAN; IMMUNOMODULATION; LUNG EMBOLISM; REVIEW; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTICOAGULANTS; ANTINEOPLASTIC PROTOCOLS; BRAIN NEOPLASMS; CEREBRAL HEMORRHAGE; FIBRINOLYTIC AGENTS; GLIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

EID: 78649632592     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32833feb73     Document Type: Review

References (25)

1. Marras CL, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughoutthe course of malignant glioma. Cancer 2000; 89:640-646.
2. Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. J Thromb Hemost 2010; 8:221-227.
3. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (Suppl 6):381-453.
4. Pan E, Tsai JS, Mitchell SB. Retrospective study of venous thromboembolic and intracranial hemorrhagic events in glioblastoma patients. Anticancer Res 2009; 29:4309-4313.
5. Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006; 24:1310-1318.
6. Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Prac Res Clin Haematol 2009; 22: 115-128.
7. Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009; 27:4865-4873.
8. Drappatz J, Wong ET, Schiff D, et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phy 2009; 73:222-227.
9. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009; 5:610-620.
10. Nalluri SR, Chu D, Keresztes, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. J Am Med Assoc 2008; 300:2277-2285.
11. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733-4740.
12. Iwamoto FM, Lamborn KR, Robins HI, et al. Phase II trial of pazopanib (GW786034), an oral multitargeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-Oncology 2010; 12:855-861.
13. Batchelor TT, Duda DG, diTomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28:2817-2823.
14. Wen P, Prados M, Schiff D, et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). J Clin Oncol 2010; 28:15s. (suppl; abstr 2006).
15. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26:5610-5617.
16. Brandes AA, Stupp R, Hau P, et al. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 2010; 46:348-354.
17. Robins HI, O'Neill A, Gilbert M, et al. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol 2008; 62:227-233.
18. Perry SL, Bohlin C, Reardon DA, et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol 2009; 95:129-134.
19. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight heparin (LMWH) thrombo prophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010 (in press).
20. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 10:146-153.
21. Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 2009; 27:4901-4911.
22. Louzada ML, Majeed H, Wells PS. Efficacy of low-molecular-weight-heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 2009; 123:837-844.
23. Nghiemphu PL, Green RM, Pope WB, et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008; 10:355-360.
24. Bartolomeo J, Norden AD, Drappatz J, et al. Safety of concurrent bevacizumab therapy and anticoagulation in high-grade glioma patients. J Clin Oncol 2010; 28:7s. (suppl; abstr 2043).
25. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27:4124-4219.